Quarterly report
Open the filing on sec.gov
AIM ImmunoTech Inc. (AIM)
NYSE: AIM · Biological Products, (No Diagnostic Substances) · Ocala, FL · filing with the SEC since 1996
The companyfiscal 2025, as filed
Revenue$88,000-48.2%
Net income-$14.0M+19.4%
Earnings per share$-8.62+72.1%
Operating cash flow-$11.0M+26.4%
Cash$3.0M+75.5%
Debt$4.5M+59.5%
Shareholders’ equity-$9.8M-640.0%
Shares, diluted1,618,617+189.0%
Return on equityn/a
The recordfrom its filings
Filings in 202673
Newest filingNov 12 · 10-Q
Annual reportMar 27, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted15
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $95,000the four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Extra proxy material
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Annual report to shareholders
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.